AbbVie Q2 Earnings Dip Amid Revenue Decline, Legal Headwinds

TL;DR

**AbbVie's Q2 numbers are a red flag; revenue and net income are down, signaling tough times ahead for the pharma giant.**

AI Summary

AbbVie Inc. reported total net revenues of $13.725 billion for the second quarter ended June 30, 2025, a decrease from $13.869 billion in the prior-year quarter. For the six months ended June 30, 2025, total net revenues were $27.350 billion, down from $27.600 billion in the same period of 2024. The company's net earnings for the second quarter of 2025 were $2.000 billion, a significant decline from $2.800 billion in Q2 2024. Diluted earnings per share also decreased to $1.13 in Q2 2025 from $1.58 in Q2 2024. Key business changes include a decrease in net revenues, indicating potential challenges in product sales or market share. Risks highlighted include ongoing litigation, such as the wholesaler lawsuit, which could result in substantial financial liabilities. The strategic outlook involves managing these legal challenges while navigating a competitive pharmaceutical landscape, as evidenced by the decline in both revenue and net income.

Why It Matters

AbbVie's Q2 2025 performance, with a revenue dip to $13.725 billion and a net income drop to $2.000 billion, signals potential challenges for investors, particularly concerning the competitive landscape and patent expirations for key drugs. Employees might face increased pressure to innovate and drive sales in a tougher market. Customers could see shifts in product availability or pricing as AbbVie adjusts its strategy. The broader market will watch how AbbVie, a pharmaceutical giant, navigates these headwinds, potentially impacting sector-wide sentiment and competitive dynamics with rivals like Pfizer and Johnson & Johnson.

Risk Assessment

Risk Level: high — The risk level is high due to a significant decline in net earnings to $2.000 billion in Q2 2025 from $2.800 billion in Q2 2024, representing a 28.6% drop. Additionally, total net revenues decreased to $13.725 billion in Q2 2025 from $13.869 billion in Q2 2024, indicating a weakening financial performance. The ongoing wholesaler lawsuit also presents a substantial, unquantified financial risk.

Analyst Insight

Investors should consider a cautious approach to ABBV stock, given the declining revenue and net income. Monitor upcoming earnings reports closely for signs of stabilization or further deterioration, and evaluate the potential impact of ongoing litigation on future profitability.

Financial Highlights

debt To Equity

N/A

revenue

$13.725B

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$2.000B

eps

$1.13

gross Margin

N/A

cash Position

N/A

revenue Growth

-1.04%

Revenue Breakdown

Key Numbers

• $13.725B — Q2 2025 Total Net Revenues (Decreased from $13.869 billion in Q2 2024, indicating a 1.04% decline.)
• $2.000B — Q2 2025 Net Earnings (Significantly decreased from $2.800 billion in Q2 2024, a 28.6% drop.)
• $1.13 — Q2 2025 Diluted EPS (Decreased from $1.58 in Q2 2024, reflecting lower profitability per share.)
• $27.350B — Six Months 2025 Total Net Revenues (Down from $27.600 billion in the same period of 2024, a 0.91% decline.)

Key Players & Entities

• AbbVie Inc. (company) — filer of the 10-Q
• $13.725 billion (dollar_amount) — total net revenues for Q2 2025
• $13.869 billion (dollar_amount) — total net revenues for Q2 2024
• $2.000 billion (dollar_amount) — net earnings for Q2 2025
• $2.800 billion (dollar_amount) — net earnings for Q2 2024
• $1.13 (dollar_amount) — diluted earnings per share for Q2 2025
• $1.58 (dollar_amount) — diluted earnings per share for Q2 2024
• wholesaler lawsuit (lawsuit) — ongoing litigation risk
• June 30, 2025 (date) — end of the reporting period for Q2
• June 30, 2024 (date) — end of the prior-year reporting period for Q2

FAQ

Risk Factors

• Wholesaler Lawsuit [high — legal]: AbbVie faces significant financial liabilities from ongoing litigation, including a lawsuit from wholesalers. The outcome of these legal proceedings could materially impact the company's financial condition and results of operations.
• Biosimilar Competition [high — market]: The company is experiencing declining revenues from key products like Humira due to the introduction of biosimilar competitors. This trend is expected to continue, impacting overall revenue growth.
• Competitive Pharmaceutical Landscape [medium — market]: AbbVie operates in a highly competitive pharmaceutical market. The success of its products is dependent on continued innovation, effective marketing, and the ability to maintain market share against rivals.
• Drug Pricing Scrutiny [medium — regulatory]: The pharmaceutical industry faces ongoing scrutiny regarding drug pricing. Potential government regulations or public pressure could impact pricing strategies and profitability.
• Supply Chain Disruptions [low — operational]: Like many global companies, AbbVie is subject to potential supply chain disruptions that could affect manufacturing and distribution of its products.

Industry Context

AbbVie operates within the highly competitive biopharmaceutical industry, characterized by significant R&D investment, patent cliffs, and increasing regulatory oversight. Key trends include the growing impact of biosimilars on established blockbusters and the rapid advancement of innovative therapies in areas like immunology and oncology. Companies are focused on pipeline development and strategic acquisitions to offset patent expirations and maintain growth.

Regulatory Implications

AbbVie faces ongoing regulatory scrutiny common in the pharmaceutical sector, particularly concerning drug pricing and market exclusivity. The company must navigate complex approval processes for new drugs and manage the impact of patent expirations and the introduction of biosimilar alternatives, which are subject to stringent regulatory standards.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the financial results discussed in the 10-Q.
• 2025-08-04: Filing Date of 10-Q — Indicates the official submission of the quarterly financial report to the SEC.
• 2025-04-01: Start of Second Quarter 2025 — Beginning of the reporting period for Q2 2025 financials.
• 2024-06-30: End of Second Quarter 2024 — Comparison period for Q2 2025 revenue and earnings.

Glossary

Diluted Earnings Per Share (EPS)

A measure of a company's profit allocated to each outstanding share of common stock, assuming all convertible securities and stock options were exercised. (Indicates the profitability on a per-share basis, which decreased to $1.13 in Q2 2025 from $1.58 in Q2 2024.)

Biosimilar

A biological product that is highly similar to a reference approved biological product, with no clinically meaningful differences in safety, purity, and potency. (The rise of biosimilars for Humira is a key factor contributing to revenue decline.)

Net Revenues

The total revenue generated from sales of products and services after deducting returns, allowances, and discounts. (Total net revenues decreased to $13.725 billion in Q2 2025 from $13.869 billion in Q2 2024.)

Net Earnings

The profit remaining after all expenses, including taxes and interest, have been deducted from total revenue. (Net earnings saw a significant drop to $2.000 billion in Q2 2025 from $2.800 billion in Q2 2024.)

Year-Over-Year Comparison

Compared to the prior year's filing, AbbVie's Q2 2025 results show a decline in total net revenues from $13.869 billion to $13.725 billion, a 1.04% decrease. Net earnings also experienced a substantial drop of 28.6%, falling from $2.800 billion to $2.000 billion. Diluted EPS decreased from $1.58 to $1.13. While some newer products show strong growth, the overall financial performance reflects challenges, particularly from the impact of biosimilar competition on key legacy products and ongoing legal risks.

From the Filing

0001551152-25-000040.txt : 20250804 0001551152-25-000040.hdr.sgml : 20250804 20250804151704 ACCESSION NUMBER: 0001551152-25-000040 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250804 DATE AS OF CHANGE: 20250804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 251179739 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 10-Q 1 abbv-20250630.htm 10-Q abbv-20250630 0001551152 false December 31 2025 Q2 http://fasb.org/us-gaap/2025#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2025#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2025#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2025#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2025#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2025#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2025#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2025#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2025#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2025#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2025#MoneyMarketFundsMember http://fasb.org/us-gaap/2025#MoneyMarketFundsMember http://fasb.org/us-gaap/2025#Revenues http://fasb.org/us-gaap/2025#Revenues http://fasb.org/us-gaap/2025#Revenues http://fasb.org/us-gaap/2025#Revenues http://fasb.org/us-gaap/2025#Revenues http://fasb.org/us-gaap/2025#Revenues http://fasb.org/us-gaap/2025#Revenues http://fasb.org/us-gaap/2025#Revenues 1 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:EUR iso4217:SEK iso4217:CAD iso4217:CHF abbv:wholesaler abbv:lawsuit abbv:claim abbv:company abbv:claims abbv:segment 0001551152 2025-01-01 2025-06-30 0001551152 us-gaap:CommonStockMember exch:XNYS 2025-01-01 2025-06-30 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2025-01-01 2025-06-30 0001551152 abbv:Sec2.125SeniorNotesdue2028Member exch:XNYS 2025-01-01 2025-06-30 0001551152 abbv:Sec2625SeniorNotesDue2028Member exch:XNYS 2025-01-01 2025-06-30 0001551152 abbv:Sec2125SeniorNotesDue2029Member exch:XNYS 2025-01-01 2025-06-30 0001551152 abbv:Sec1.250SeniorNotesdue2031Member exch:XNYS 2025-01-01 2025-06-30 0001551152 2025-07-29 0001551152 2025-04-01 2025-06-30 0001551152 2024-04-01 2024-06-30 0001551152 2024-01-01 2024-06-30 0001551152 2025-06-30 0001551152 2024-12-31 0001551152 us-gaap:CommonStockMember 2024-03-31 0001551152 us-gaap:TreasuryStockCommonMember 2024-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001551152 us-gaap:RetainedEarningsMember 2024-03-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001551152 us-gaap:NoncontrollingInterestMember 2024-03-31 0001551152 2024-03-31 0001551152 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001551152 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001551152 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001551152 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001551152 us-gaap:CommonStockMember 2024-06-30 0001551152 us-gaap:TreasuryStockCommonMember 2024-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001551152 us-gaap:RetainedEarningsMember 2024-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001551152 us-gaap:NoncontrollingInterestMember 2024-06-30 0001551152 2024-06-